Mirtazapine reduces methamphetamine use in phase 3 trial
Mirtazapine cuts meth use days more than placebo in adults with severe addiction
In a phase 3 RCT, mirtazapine 30 mg daily for 12 weeks led to a greater reduction in methamphetamine use days compared to placebo, with a me…
Adults with severe methamphetamine use disorder took less meth when on mirtazapine compared to placebo, with fewer days of use over 12 weeks…
ETVAX shows 48.2% efficacy against moderate-to-severe ETEC diarrhoea in Gambian children despite missing primary endpoint
Early trial shows ETVAX vaccine linked to reduced diarrhoea in Gambian children
This phase 2b randomized controlled trial enrolled 4936 Gambian children aged 6 to 18 months. ETVAX demonstrated 48.2% efficacy against mode…
A phase 2b trial found an ETEC vaccine linked to lower diarrhoea rates in young children, though the main goal was not reached.
Tirzepatide improves waist-to-height ratio in adults with obesity or overweight
Tirzepatide improves waist-to-height ratio in obesity and prediabetes
A post-hoc analysis of a Phase 3 RCT found that tirzepatide (10/15 mg) improved waist-to-height ratio (WHtR) in adults with obesity or overw…
A new analysis finds tirzepatide helps more people with obesity achieve a healthier waist-to-height ratio, a key measure of belly fat risk.
Higher admission WBC predicts favorable methylprednisolone effect after thrombectomy
Higher white blood cell counts linked to better methylprednisolone effects in stroke patients
This secondary analysis of a randomized, placebo-controlled trial evaluated 1201 patients with anterior-circulation large-vessel occlusion s…
A secondary analysis suggests higher white blood cell counts may predict better outcomes when adding methylprednisolone to stroke treatment …
Darvadstrocel shows 48.8% combined remission in Crohn's perianal fistulas, not superior to placebo
Darvadstrocel showed no better results than placebo for Crohn's disease fistulas
This Phase 3 randomized trial in adults with Crohn's disease and complex perianal fistulas found that darvadstrocel did not achieve a statis…
A major trial found darvadstrocel did not improve closure of Crohn's fistulas compared to placebo, showing no significant benefit for patien…
Estetrol 15 mg and 20 mg reduce vasomotor symptom frequency and severity in postmenopausal women
Estetrol reduces hot flashes in women with and without hysterectomies
This phase 3 randomized, double-blind, placebo-controlled trial enrolled 640 hysterectomized and non-hysterectomized participants aged 40 to…
A phase 3 trial found that estetrol significantly reduced the frequency and severity of moderate to severe vasomotor symptoms in postmenopau…
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
Oral icotrokinra shows strong results for moderate-to-severe plaque psoriasis
This systematic review and meta-analysis evaluates icotrokinra for moderate-to-severe plaque psoriasis in 1951 patients. The pooled analysis…
A new analysis finds oral icotrokinra helps clear skin faster than placebo in patients with moderate-to-severe plaque psoriasis.
Brexpiprazole improves PANSS scores by 0.19 Cohen's d in early-episode schizophrenia versus placebo
Brexpiprazole helps early schizophrenia symptoms more than placebo in adults and teens
This post hoc analysis of Phase 3 trials evaluated brexpiprazole versus placebo in 476 adults and adolescents aged 13-35 years with early-ep…
A look at trial data shows brexpiprazole improved symptoms and daily functioning better than placebo for people with early schizophrenia.
Subcutaneous anifrolumab improves BICLA response by 15.5% in moderate to severe SLE
Anifrolumab injection improves lupus outcomes in trial
This phase 3 RCT in 367 adults with moderate to severe SLE found that subcutaneous anifrolumab 120 mg weekly plus standard therapy improved …
A weekly injection of anifrolumab helped more people with lupus achieve disease control than placebo, a phase 3 trial shows.
Netarsudil plus latanoprost cuts diurnal IOP 2.36 mmHg vs latanoprost alone in Japanese glaucoma
Adding netarsudil to latanoprost lowers eye pressure faster in Japanese patients with glaucoma
This Phase III randomized controlled trial in 246 Japanese participants with primary open-angle glaucoma or ocular hypertension found that n…
Japanese patients with glaucoma saw lower eye pressure when adding netarsudil to their current latanoprost drops compared to a placebo plus …
Oral Semaglutide Failed to Slow Clinical Progression in Early Alzheimer's Disease Across Global Phase 3 Trials
Oral semaglutide did not slow Alzheimer's disease progression in early trials
In large phase 3 trials, oral semaglutide showed no benefit over placebo for patients with early Alzheimer's disease. The drug did not impro…
A large trial found that taking oral semaglutide offered no benefit over placebo for people with early Alzheimer's disease.
Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo
Ocrelizumab reduces disability risk for primary progressive multiple sclerosis patients
This phase 3b trial evaluated intravenous ocrelizumab versus placebo in patients with primary progressive multiple sclerosis. The study foun…
A large trial found ocrelizumab significantly lowers the risk of disability progression in patients with primary progressive multiple sclero…
All placebo Articles
- Mirtazapine reduces methamphetamine use in phase 3 trial
- ETVAX shows 48.2% efficacy against moderate-to-severe ETEC diarrhoea in Gambian children despite missing primary endpoint
- Higher admission WBC predicts favorable methylprednisolone effect after thrombectomy
- Darvadstrocel shows 48.8% combined remission in Crohn's perianal fistulas, not superior to placebo
- Estetrol 15 mg and 20 mg reduce vasomotor symptom frequency and severity in postmenopausal women
- Brexpiprazole improves PANSS scores by 0.19 Cohen's d in early-episode schizophrenia versus placebo
- Tirzepatide improves waist-to-height ratio in adults with obesity or overweight
- Subcutaneous anifrolumab improves BICLA response by 15.5% in moderate to severe SLE
- Netarsudil plus latanoprost cuts diurnal IOP 2.36 mmHg vs latanoprost alone in Japanese glaucoma
- Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
- Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo
- Oral Semaglutide Failed to Slow Clinical Progression in Early Alzheimer's Disease Across Global Phase 3 Trials
- Clobetasol ophthalmic nanoemulsion reduces anterior chamber cells and pain after cataract surgery
- Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
- Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
- Ursodeoxycholic acid reduces ALT and fibrosis in chronic liver disease patients
- Olezarsen showed no significant difference versus placebo in noncalcified plaque volume change over 12 months in adults with moderate hypertriglyceridemia
- Post-hoc safety analysis of intramuscular adintrevimab for COVID-19 prophylaxis reports tolerability data
- Vunakizumab improves ASAS20 response in active radiographic axial spondyloarthritis at 16 weeks
- MUSKARDIA shows protective trend in stable CAD with reduced eGFR
- Plozasiran reduces recurrent pancreatitis in familial chylomicronaemia syndrome post hoc analysis
- Romosozumab improves shear bone strength in postmenopausal women with osteoporosis in BCT substudies
- Adjunctive JNJ-42165279 fails to improve depression in SSRI/SNRI inadequate responders
- Semaglutide improves physical quality of life in schizophrenia with prediabetes
- Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity
- Dry NaCl Inhalation Fails to Improve Mucociliary Clearance in COPD
- Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance
- Oral Sodium Butyrate Reduces Weight in Overweight Adults Without Diabetes
- Essential phospholipids reduced hepatic steatosis and improved HbA1c in patients with MASLD and type 2 diabetes over 6 months
- Glenzocimab fails to improve outcomes in acute ischemic stroke thrombolysis
- Memantine improved neuropathy severity and pain scores versus placebo in CIPN over eight weeks
- Semaglutide high dose for weight reduction in people with Type 2 Diabetes
- Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
- Modified Banxia Xiexin Decoction plus chemotherapy shows favorable trends in advanced colorectal cancer
- Baseline Cytokine Levels Linked to Placebo Response in Cancer Dyspnea Trial
- GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial
- Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
- Memantine reduced PAC burden and new-onset AF in a Phase 2 randomized trial of 241 adults
- Secukinumab 300 mg subcutaneously failed to demonstrate overall response in adults with active Graves orbitopathy versus placebo
- In an RCT, dutasteride significantly reduced total International Prostate Symptom Score in men with lower urinary tract symptoms over 24 months
- AI endoscopic score shows better agreement with ulcerative colitis remission than Mayo score in RCT
- TTI-0102 Improves Fatigue Scores in MELAS Syndrome Patients During Randomized Phase 2 Trial
- Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis
- Deuruxolitinib 8 or 12 mg BID improved SALT20 response versus placebo in severe alopecia areata
- Phase 2 RCT of IV CN-105 in older adults undergoing noncardiac surgery shows fewer grade 2+ adverse events versus placebo
- Phase 2 trial tests single-dose IV iron isomaltoside in severe aortic stenosis with iron deficiency
- Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
- Memantine reduces opioid use but not pain in knee osteoarthritis patients after surgery
- Pyridostigmine improves symptoms and reduces costs in adults with AChR MG in a crossover trial
- AZD7442 showed no benefit over placebo and increased rehospitalization risk in hospitalized COVID-19 adults
- Pitavastatin showed no difference in health-related quality of life compared with placebo in people with HIV
- Nerinetide showed no significant association with brain volume changes in stroke patients receiving endovascular therapy
- Galantamine showed no cognitive benefit in people with HIV-associated neurocognitive disorders
- Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history
- Lecanemab slowed cognitive decline in ApoE4 non-carriers and heterozygotes with early Alzheimer's disease
- N-acetylcysteine protocol study for early-onset preeclampsia progression in Lagos, Nigeria
- Phase 2 trial finds mezagitamab increases platelet counts in adults with persistent or chronic ITP
- Hydroxychloroquine did not prevent SLE progression in incomplete lupus patients in randomized trial